BCRX (BioCryst Pharmaceuticals) Moat Score: 5/10 (As of Jun. 29, 2026)


BCRX BioCryst Pharmaceuticals Inc BCRX
64 GF Score
Price $9.56
GF Value $12.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Moat Score?

BioCryst Pharmaceuticals BCRX -4.21% 64 Moat Score is 5 as of Jun. 29, 2026. GuruFocus rates BCRX with a GF Score™ of 64/100 and a GF Value™ of $12.75 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks better than 94.66% on this metric.

BioCryst Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

BioCryst Pharmaceuticals has Narrow Moat: BioCryst Pharmaceuticals Inc has a solid narrow moat due to its valuable intellectual property and patents in the pharmaceutical industry. The company benefits from regulatory barriers and a strong R&D pipeline, but it lacks the market dominance and pricing power needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioCryst Pharmaceuticals might have Narrow Moat - Solid narrow moat.

BioCryst Pharmaceuticals  (NAS:BCRX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioCryst Pharmaceuticals Moat Score Related Terms

BCRX vs SUPN, PBH, AMLX: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Moat Score falls into.


BCRX
64GF Score
BioCryst Pharmaceuticals Inc BCRX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
BioCryst Pharmaceuticals (BCRX) has a Moat Score of 5 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #55 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is BioCryst Pharmaceuticals' Moat Score too high?
BioCryst Pharmaceuticals' current Moat Score is 5. Based on the distribution chart, BioCryst Pharmaceuticals ranks #55 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Moat Score compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #55 out of 1030 companies for Moat Score. This places BioCryst Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. BioCryst Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.75, compared to a current price of $9.56 — trading 25% below its estimated fair value. The current Moat Score is 5. BioCryst Pharmaceuticals' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Moat Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.56 is trading 25% below its estimated GF Value™ of $12.75. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Moat Score: 5
  • GF Value™: $12.75 vs. price of $9.56 (25% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
64GF Score

Get the complete analysis for BCRX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.56
Price
$12.75
GF Value